AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of GBP 177.02 billion. The enterprise value is 197.00 billion.

Market Cap	177.02B
Enterprise Value	197.00B

Important Dates

The next estimated earnings date is Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	Feb 21, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.06%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 31.50.

PE Ratio	31.50
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.79, with an EV/FCF ratio of 24.82.

EV / Earnings	35.06
EV / Sales	4.56
EV / EBITDA	13.79
EV / EBIT	19.12
EV / FCF	24.82

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.75.

Current Ratio	0.93
Quick Ratio	0.67
Debt / Equity	0.75
Debt / EBITDA	1.70
Debt / FCF	3.07
Interest Coverage	9.22

Financial Efficiency

Return on equity (ROE) is 17.59% and return on invested capital (ROIC) is 11.53%.

Return on Equity (ROE)	17.59%
Return on Assets (ROA)	7.88%
Return on Invested Capital (ROIC)	11.53%
Return on Capital Employed (ROCE)	16.97%
Revenue Per Employee	458,026
Profits Per Employee	59,590
Employee Count	94,300
Asset Turnover	0.53
Inventory Turnover	1.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +10.55% in the last 52 weeks. The beta is 0.16, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	+10.55%
50-Day Moving Average	67.62
200-Day Moving Average	75.10
Relative Strength Index (RSI)	68.65
Average Volume (20 Days)	9,560

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of GBP 43.19 billion and earned 5.62 billion in profits. Earnings per share was 3.59.

Revenue	43.19B
Gross Profit	35.49B
Operating Income	10.33B
Pretax Income	6.94B
Net Income	5.62B
EBITDA	14.03B
EBIT	10.33B
Earnings Per Share (EPS)	3.59

Full Income Statement

Balance Sheet

The company has 4.41 billion in cash and 24.33 billion in debt, giving a net cash position of -19.92 billion.

Cash & Cash Equivalents	4.41B
Total Debt	24.33B
Net Cash	-19.92B
Net Cash Per Share	n/a
Equity (Book Value)	32.65B
Book Value Per Share	21.01
Working Capital	-1.63B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 9.47 billion and capital expenditures -1.54 billion, giving a free cash flow of 7.94 billion.

Operating Cash Flow	9.47B
Capital Expenditures	-1.54B
Free Cash Flow	7.94B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.18%, with operating and profit margins of 23.91% and 13.01%.

Gross Margin	82.18%
Operating Margin	23.91%
Pretax Margin	16.07%
Profit Margin	13.01%
EBITDA Margin	32.49%
EBIT Margin	23.91%
FCF Margin	18.38%

Dividends & Yields

This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.60%.

Dividend Per Share	1.20
Dividend Yield	1.60%
Dividend Growth (YoY)	6.92%
Years of Dividend Growth	n/a
Payout Ratio	65.80%
Buyback Yield	-0.06%
Shareholder Yield	1.54%
Earnings Yield	3.17%
FCF Yield	4.48%

Dividend Details

Stock Splits

The last stock split was on April 8, 1998. It was a forward split with a ratio of 3.

Last Split Date	Apr 8, 1998
Split Type	Forward
Split Ratio	3

Scores

AstraZeneca has an Altman Z-Score of 3.15.

Altman Z-Score	3.15
Piotroski F-Score	n/a